CN105646498A - Crystal form F of ibrutinib and preparation method - Google Patents

Crystal form F of ibrutinib and preparation method Download PDF

Info

Publication number
CN105646498A
CN105646498A CN201610114027.2A CN201610114027A CN105646498A CN 105646498 A CN105646498 A CN 105646498A CN 201610114027 A CN201610114027 A CN 201610114027A CN 105646498 A CN105646498 A CN 105646498A
Authority
CN
China
Prior art keywords
degrees
crystal
shandong
buddhist nun
crystal formation
Prior art date
Application number
CN201610114027.2A
Other languages
Chinese (zh)
Inventor
孙霖
Original Assignee
孙霖
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 孙霖 filed Critical 孙霖
Priority to CN201610114027.2A priority Critical patent/CN105646498A/en
Publication of CN105646498A publication Critical patent/CN105646498A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Abstract

The invention discloses a crystal form F of ibrutinib. The crystal form F is characterized in that X-ray powder diffraction (X-RPD) which adopts Cu-Kalpha radiation and is represented with a 2theta angle has diffraction peaks in positions at angles of 3.7 degrees plus or minus 0.2 degrees, 6.7 degrees plus or minus 0.2 degrees, 13.2 degrees plus or minus 0.2 degrees, 16.1 degrees plus or minus 0.2 degrees, 19.1 degrees plus or minus 0.2 degrees, 20.0 degrees plus or minus 0.2 degrees, 23.8 degrees plus or minus 0.2 degrees and 24.6 degrees plus or minus 0.2 degrees. Related solvents in a preparation process of the crystal form F are cheap, the conditions are mild, the operation is simple, good controllability and reproducibility are realized, further, the prepared crystal form has great stability, the HPLC (high performance liquid chromatography) purity is higher than 99%, and the phenomenon of crystal transformation can be avoided; besides, the solubility is high, the dissolubility is good, and the bioavailability is high.

Description

According to Shandong for Buddhist nun crystal formation F and preparation method
Technical field
The present invention relates to medicinal chemistry art, in particular it relates to according to Shandong for the crystal formation of Buddhist nun, and the preparation method of crystal formation and purposes.
Background technology
It is the pioneering new drug of a kind of oral bruton's tyrosine kinase (BTK) inhibitor for Buddhist nun (Ibrutinib) according to Shandong, by Pharmacyclics company of the U.S. and Johson & Johnson's joint research and development, commodity are called Imbruvica, its chemical name is: 1-[(3R)-3-[4-amino-3-(4-Phenoxyphenyl)-1H-pyrazolo [3,4-d] pyrimidine-1-base]-piperidino]-2-propylene-1-ketone, structural formula is as follows:
According to Shandong for Buddhist nun by with target protein Btk activity site cysteine residue (Cys-481) optionally covalent bond, irreversibility ground suppress BTK, thus effectively stop tumor move to the lymphoid tissue being adapted to tumor growth environment from B cell. In November, 2013, FDA (Food and Drug Adminstration) (FDA) ratifies its listing, for treating a kind of rare aggressive leukemia lymphoma mantle cell (MCL), in July, 2014, FDA ratified its treatment for chronic lymphocytic leukemia (CLL).
The patent WO2013/184572 of Pharmacyclics company of U.S. application in 2013 discloses the six kinds of crystal formations replacing Buddhist nun according to Shandong, wherein crystal formation D is methyl isobutyl ketone solvent compound, crystal formation E is toluene solvate, and crystal formation D is Methanol Solvate, is all not suitable for pharmaceutical formulation. In its excess-three kind crystal formation, reporting crystal form B hygroscopicity according to WO2013/184572 relatively larger, crystal form A is not easy moisture absorption by contrast, it does not have the stability of report crystal C and solubility data. Therefore, in six kinds of crystal formations, only crystal form A is suitable for pharmaceutical formulation, and the crystal form A of its report has three kinds of preparation methoies: method one is will to be suspended in the organic solvent of 10 times of volumes for Buddhist nun's amorphous article according to Shandong, heat in an oscillator to 50 DEG C, vibrate 1 hour, add the organic solvent of 30 times of volumes, be again heated to 50 DEG C and vibrate 1 hour, then it is cooled to 0 DEG C with the speed of 0.1 DEG C/min, filtering, the solid obtained is crystal form A, and filtrate also obtains crystal form A by pin hole slow evaporation. This kind of method complex operation, and because consumption of organic solvent is 40 times, so the product yield that is filtrated to get of first time is low, although and from filtrate, also can obtain product, but consuming time oversize; Method two is will to be suspended in the organic solvent of 1-10 times of volume for Buddhist nun's amorphous article according to Shandong, and then sealed reaction bottle seals 5 days in curing chamber, is filtrated to get crystal form A.This kind of method is same consuming time long and it needs to special installation; Method three is will to replace Buddhist nun's heating for dissolving in the methanol of 10 times of volumes according to Shandong, add water, then heat up under insulation, is subsequently cooled to room temperature and continues stirring 16 hours, obtaining crystal form A, and yield is 80%. The complex operation of this kind of method, has intensification repeatedly and cooling in operation, the bad control of production process.
Suzhou crystalline substance cloud CN104327085A discloses another crystal form A (hereinafter referred to crystal form A '), the preparation method of its report has three kinds: method one, to replace Buddhist nun's dissolving crude product in the mixed solution of isopropanol and normal heptane according to Shandong, at room temperature stirring with the speed of 750 turns per minute and obtain crystal form A ', such high-revolving stirring industrializing implementation is highly difficult; Method two, will according to Shandong for Buddhist nun's dissolving crude product in the mixed solvent of isopropanol and normal heptane, and drop to 5 DEG C with the cooling rate of 0.1 DEG C/min from 50 DEG C and obtain crystal form A, so accurate cooling rate is difficult to control; Method three, according to Shandong for Buddhist nun's dissolving crude product in acetone, will be slow added into normal heptane, and stirring obtains crystal form A in 1 day under the rotating speed of 1000 turns per minute, and the rotating speed that this method ratio method one requires is higher, and industrialization is more difficult to realize. And have been reported discovery when repeating these methods, and poor reproducibility, somewhat control bad to obtain crystal form A disclosed in WO2013/184572. Additionally, existing dosage form water solublity is little, oral organism-absorbing availability is relatively low.
Therefore, this area needs the crystal formation that research and development are new badly, it is desirable to preparation method is simple, and Heat stability is good, hygroscopicity is low, is produced on a large scale.
Summary of the invention
For above-mentioned prior art Problems existing, the present invention provides a kind of novel crystal forms F according to Shandong for Buddhist nun, and preparation method is simply controlled, is produced on a large scale, Heat stability is good, and dissolubility is high and dissolution is good, and bioavailability is high.
Crystal formation F according to Shandong for Buddhist nun of the present invention, it is characterized in that, use Cu-K �� radiation, the X-ray powder diffraction (X-RPD) represented with 2 �� angles at 3.7 �� 0.2 ��, 6.7 �� 0.2 ��, 13.2 �� 0.2 ��, 16.1 �� 0.2 ��, 19.1 �� 0.2 ��, 20.0 �� 0.2 ��, 23.8 �� 0.2 ��, there is diffraction maximum at 24.6 �� 0.2 �� of places.
Further, described crystal formation F, use Cu-K �� radiation, the X-ray powder diffraction represented with 2 �� angles at 3.7 �� 0.2 ��, 6.7 �� 0.2 ��, 11.6 �� 0.2 ��, 13.2 �� 0.2 ��, 16.1 �� 0.2 ��, 19.1 �� 0.2 ��, 20.0 �� 0.2 ��, 23.8 �� 0.2 ��, 24.6 �� 0.2 ��, 26.2 �� 0.2 ��, 27.8 �� 0.2 ��, 28.1 �� 0.2 ��, there is diffraction maximum at 31.8 �� 0.2 �� of places.
The preparation method of described crystal formation: replacing Buddhist nun's amorphous article to add in the mixed solution of isopropanol and methanol according to Shandong, stir 10 hours, add water, continue stirring 2 hours, filter, vacuum drying obtains crystal F.
The described ratio replacing Buddhist nun and mixed solution according to Shandong is 1g:10ml. The volume ratio of described isopropanol and methanol is 2:1. The addition volume of described water is with the volume of mixed solution. Described vacuum drying temperature is 40 degree.
The present invention also provides for a kind of pharmaceutical composition, including described crystal formation F and pharmaceutically acceptable excipient.
The present invention also provides for a kind of pharmaceutical composition, including the combination of described crystal formation F and the second pharmacological active substance.
Solvent involved by crystal formation preparation process of the present invention is cheap, and mild condition is simple to operate, has good controllability and reproducibility, and the crystal formation prepared has fabulous stability, HPLC high purity more than 99%, does not have and turns brilliant phenomenon.Additionally, dissolubility is high and dissolution is good, bioavailability is high.
Accompanying drawing explanation
Fig. 1 is the X-RPD collection of illustrative plates of crystal formation F of the present invention.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is expanded on further. Should be understood that these embodiments are merely to illustrate the present invention rather than restriction the scope of the present invention. The experimental technique of unreceipted actual conditions in the following example, generally conventionally condition. Experiment material used in following example and reagent all can obtain from commercially available channel if no special instructions.
Embodiment 1
Buddhist nun amorphous article 10g is replaced to add in the mixed solution (volume ratio of isopropanol and methanol is 2:1) of 100ml isopropanol and methanol according to Shandong, heating makes dissolving to backflow, stir 10 hours after dissolving, add water 100ml, stirs 2 hours, filters, 40 DEG C of vacuum dryings obtain crystal F, using Cu-K �� radiation, the X-ray powder diffraction represented with 2 �� angles is as it is shown in figure 1, HPLC purity is for 99.90%.
Mensuration about the crystal formation of embodiment 1 preparation:
1. stability test
Example 1 prepare when being placed on 35 DEG C according to Shandong for Buddhist nun's crystal formation F sample, investigate and placing the stability of 1 month, 3 months, 6 months, result of the test is in Table 1. (method of concrete study on the stability is referred to the method for 2010 editions second annex XIXC of Chinese Pharmacopoeia; Purity detecting HPLC method, it is possible to reference to the method for 2010 editions second annex VD of Chinese Pharmacopoeia)
Table 1 replaces the stability test result of Buddhist nun crystal formation F according to Shandong
Purity % Crystal formation
1 month 99.90 Same Fig. 1
3 months 99.89 Same Fig. 1
6 months 99.88 Same Fig. 1
2. solubility test
Measure the medium (phosphate buffer of water, 0.01mol/LHCl solution and pH6.8) of 10ml respectively in cillin bottle, add excessive Shandong for Buddhist nun crystal formation F, cillin bottle is sealed and puts 37 DEG C of constant temperature water baths stirrings 1 hour, through 0.45 ��m of membrane filtration, taking subsequent filtrate and measure absorbance respectively at the wavelength place of 284nm, result is in Table 2.
(�� g/ml) is compared for Buddhist nun crystal formation F dissolubility in different medium in table 2 Shandong
Water 0.01mol/L HCl solution The phosphate buffer of pH6.8
Buddhist nun crystal formation F is replaced in Shandong 11.63 9.97 7.75
3. dissolution determination
For Buddhist nun crystal formation F, Shandong being crossed 80 mesh sieves, weighs powder 10mg after sieving, according to two annex XC the second method (paddle method) devices of " Chinese Pharmacopoeia " version in 2010, dissolution medium is 500ml water respectively, rotating speed 100rpm, temperature 37 DEG C. Respectively at 10,15,30,45,60,90min sample 3ml, and fluid infusion 3ml in time, 0.22 ��m of filter membrane crossed by sample, and sample introduction, in HPLC, calculates dissolution. Result is in Table 3.
Buddhist nun crystal formation F dissolution percentage amounts/% in water is replaced in table 3 Shandong
Time (min) Buddhist nun crystal formation F is replaced in Shandong
10 16.98
15 24.92
30 38.31
45 42.16
60 46.38
90 47.11

Claims (9)

1. the crystal formation F of Buddhist nun is replaced according to Shandong, it is characterized in that, use Cu-K �� radiation, the X-ray powder diffraction (X-RPD) represented with 2 �� angles at 3.7 �� 0.2 ��, 6.7 �� 0.2 ��, 13.2 �� 0.2 ��, 16.1 �� 0.2 ��, 19.1 �� 0.2 ��, 20.0 �� 0.2 ��, 23.8 �� 0.2 ��, there is diffraction maximum at 24.6 �� 0.2 �� of places.
2. the crystal formation F according to Shandong for Buddhist nun according to claim 1, it is characterised in that use Cu-K �� radiation, the X-ray powder diffraction represented with 2 �� angles at 3.7 �� 0.2 ��, 6.7 �� 0.2 ��, 11.6 �� 0.2 ��, 13.2 �� 0.2 ��, 16.1 �� 0.2 ��, 19.1 �� 0.2 ��, 20.0 �� 0.2 ��, 23.8 �� 0.2 ��, 24.6 �� 0.2 ��, 26.2 �� 0.2 ��, 27.8 �� 0.2 ��, 28.1 �� 0.2 ��, there is diffraction maximum at 31.8 �� 0.2 �� of places.
3. the preparation method replacing the crystal formation F of Buddhist nun according to Shandong, it is characterised in that replace Buddhist nun's amorphous article to add in the mixed solution of isopropanol and methanol according to Shandong, stir 10 hours, add water, continues stirring 2 hours, and filtration, vacuum drying obtains crystal F.
4. method according to claim 3, it is characterised in that the described ratio replacing Buddhist nun and mixed solution according to Shandong is 1g:10ml.
5. method according to claim 3, it is characterised in that the volume ratio of described isopropanol and methanol is 2:1.
6. method according to claim 3, it is characterised in that the addition volume of described water is with the volume of mixed solution.
7. method according to claim 3, it is characterised in that described vacuum drying temperature is 40 degree.
8. a pharmaceutical composition, including crystal formation F described in claim 1 and pharmaceutically acceptable excipient.
9. a pharmaceutical composition, including the combination of crystal formation F and the second pharmacological active substance described in claim 1.
CN201610114027.2A 2016-03-01 2016-03-01 Crystal form F of ibrutinib and preparation method CN105646498A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610114027.2A CN105646498A (en) 2016-03-01 2016-03-01 Crystal form F of ibrutinib and preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610114027.2A CN105646498A (en) 2016-03-01 2016-03-01 Crystal form F of ibrutinib and preparation method

Publications (1)

Publication Number Publication Date
CN105646498A true CN105646498A (en) 2016-06-08

Family

ID=56492008

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610114027.2A CN105646498A (en) 2016-03-01 2016-03-01 Crystal form F of ibrutinib and preparation method

Country Status (1)

Country Link
CN (1) CN105646498A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106117214A (en) * 2016-06-29 2016-11-16 上海创诺医药集团有限公司 According to Shandong for Buddhist nun's novel crystal forms and preparation method thereof
US9828383B1 (en) 2012-06-04 2017-11-28 Pharmacyclic s LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
US10010507B1 (en) 2015-03-03 2018-07-03 Pharmacyclics Llc Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
EP3669867A1 (en) 2018-12-21 2020-06-24 Synthon B.V. Pharmaceutical composition comprising ibrutinib

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102887900A (en) * 2006-09-22 2013-01-23 药品循环公司 Inhibitors of bruton's tyrosine kinase
CN103121999A (en) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 Method for synthesizing tyrosine kinase inhibitor PCI-32765
CN103626774A (en) * 2013-11-20 2014-03-12 苏州明锐医药科技有限公司 Preparation method of Ibrutinib
CN103923084A (en) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 Several new crystal forms and preparation methods thereof
CN104736178A (en) * 2012-06-04 2015-06-24 药品循环公司 Crystalline forms of a Bruton's tyrosine kinase inhibitor
WO2015145415A2 (en) * 2014-03-27 2015-10-01 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
CN105859721A (en) * 2015-01-22 2016-08-17 浙江京新药业股份有限公司 Method for preparing ibrutinib

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102887900A (en) * 2006-09-22 2013-01-23 药品循环公司 Inhibitors of bruton's tyrosine kinase
CN104736178A (en) * 2012-06-04 2015-06-24 药品循环公司 Crystalline forms of a Bruton's tyrosine kinase inhibitor
CN103121999A (en) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 Method for synthesizing tyrosine kinase inhibitor PCI-32765
CN103626774A (en) * 2013-11-20 2014-03-12 苏州明锐医药科技有限公司 Preparation method of Ibrutinib
CN103923084A (en) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 Several new crystal forms and preparation methods thereof
WO2015145415A2 (en) * 2014-03-27 2015-10-01 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
CN105859721A (en) * 2015-01-22 2016-08-17 浙江京新药业股份有限公司 Method for preparing ibrutinib

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANON.: "Crystalline form of (R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine", 《IP.COM JOURNAL》 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266540B2 (en) 2012-06-04 2019-04-23 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US9828383B1 (en) 2012-06-04 2017-11-28 Pharmacyclic s LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
US10752634B2 (en) 2012-06-04 2020-08-25 Pharmacyclics Llc Crystalline forms of a brutons tyrosine kinase inhibitor
US10065968B2 (en) 2012-06-04 2018-09-04 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US10106548B2 (en) 2012-06-04 2018-10-23 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10125140B1 (en) 2012-06-04 2018-11-13 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US10294231B2 (en) 2012-06-04 2019-05-21 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10294232B2 (en) 2012-06-04 2019-05-21 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10961251B1 (en) 2012-06-04 2021-03-30 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10213386B2 (en) 2015-03-03 2019-02-26 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US10828259B2 (en) 2015-03-03 2020-11-10 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US10010507B1 (en) 2015-03-03 2018-07-03 Pharmacyclics Llc Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
CN106117214A (en) * 2016-06-29 2016-11-16 上海创诺医药集团有限公司 According to Shandong for Buddhist nun's novel crystal forms and preparation method thereof
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
EP3669867A1 (en) 2018-12-21 2020-06-24 Synthon B.V. Pharmaceutical composition comprising ibrutinib
WO2020127912A1 (en) 2018-12-21 2020-06-25 Synthon B.V. Pharmaceutical composition comprising ibrutinib

Similar Documents

Publication Publication Date Title
CN104327085B (en) Crystal formation A of PCI-32765 and preparation method thereof
CN103641822B (en) A kind of Ka Gelie purifies compound and pharmaceutical composition thereof
KR101470715B1 (en) Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof
CN106046088B (en) Crystal form H3 of rope fluorine cloth Wei and preparation method thereof
Chen et al. Liquid chromatography of active principles in Sophora flavescens root
CN104130302A (en) Crystal form of nucleotide medicines and preparation method of crystal form
CN104961671B (en) Crystal formation of the tartrate of N (4 luorobenzyl) N (base of 1 methyl piperidine 4) N ' (4 (2 methyl propoxyl group) phenyl methyl) urea half and preparation method thereof
CN102086195B (en) Dasatinib polymorphic substance as well as preparation method and medicinal composition thereof
CN103550159A (en) Novel solid forms of bendamustine hydrochloride
CN100364994C (en) Crystal form of Peimeiqusai disodium and its preparation
CN101869551B (en) Temozolomide freeze-dried preparation
CN105601635B (en) Ba Ruike is for Buddhist nun phosphatic A crystal formations, H crystal form and I crystal and preparation method thereof
EP3141540B1 (en) Preparation of a crystalline form of chlorogenic acid
CN103864819B (en) A kind of ceftazidime compound and pharmaceutical composition thereof
CN101671314B (en) Uloric crystal and preparation method thereof
CN102924434B (en) Dexrabeprazole sodium monohydrate crystal form and preparation method thereof
CN104892612B (en) A kind of Ai Delibu amorphous article and preparation method thereof
CN105669581A (en) Angiotensin receptor antagonist/neutral endopeptidase inhibitor composite
CN105693731A (en) Baricitinib polymorph A and preparation method thereof
CN102336801B (en) Abiraterone acetate polymorphic substance and pharmaceutical composition
CN106008468B (en) Bo Maxini A crystal form, B crystal form, C crystal form and preparation method thereof
CN101277694A (en) Novel crystal forms of irinotecan hydrochloride
CN106916100A (en) A kind of E benzamide compound and its pharmaceutical formulation
CN106188194A (en) Suo Feibuwei monocrystalline and preparation method and purposes
CN103524532B (en) Ceftizoxime sodium compound crystal form, and preparing method and pharmaceutical preparation thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160608